Bortezomib.
Tariman
Joseph D
JD
Multiple Myeloma Program, Department of Medicine, Division of Hematology/Oncology, Northwestern University Medical Faculty Foundation, Chicago, IL, USA. jtariman@nmff.org
Lemoine
Colleen
C
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000069286:Bortezomib; D004347:Drug Interactions; D006207:Half-Life; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy; D009730:Nursing Assessment; D010353:Patient Education as Topic; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib